Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

polycefin

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Introduction: A significant clinical problem with brain metastatic (BM) tumors is drug delivery and diagnostic imaging to verify… Expand
2013
2013
SUMMARY Dynamic contrast enhancement is shown to allow differential MRI detection of human primary brain and metastatic breast… Expand
  • figure 1
  • figure 2
  • figure 4
  • figure 3
2013
2013
A significant clinical problem with brain metastatic (BM) tumors is drug delivery and diagnostic imaging to verify MRI… Expand
Highly Cited
2012
Highly Cited
2012
Doxorubicin (DOX) is currently used in cancer chemotherapy to treat many tumors and shows improved delivery, reduced toxicity and… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
2010
2010
Objective: We have developed an efficient nanobipolymer drug delivery system Polycefin based on natural-derived biodegradable… Expand
2009
2009
CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts Abstract #2124 Objective: Nanobioconjugate engineered based on… Expand
Highly Cited
2008
Highly Cited
2008
A new prototype of polymer-derived drug delivery system, the nanoconjugate Polycefin, was tested for its ability to accumulate in… Expand
Review
2008
Review
2008
Nanoconjugates are emerging as promising drug-delivery vehicles because of their multimodular structure enabling them to actively… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2006
Highly Cited
2006
A new prototype of nanoconjugate, Polycefin, was synthesized for targeted delivery of antisense oligonucleotides and monoclonal… Expand
Highly Cited
2006
Highly Cited
2006
We have previously shown that laminin-8, a vascular basement membrane component, was overexpressed in human glioblastomas… Expand
  • figure 2
  • figure 1
  • figure 3
  • figure 4
  • figure 5